Here's Why Puma Biotechnology Fell 17.2% in April | The Motley Fool
Puma shares nearly triple on drug news, but options smell 'fishy'
Should You Buy Puma Biotechnology Inc (PBYI) Stock Tuesday?
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Puma Biotechnology, Inc.
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Alan H. Auerbach - Los Angeles Business Journal
Goldman Sachs Group Cuts Stake in Puma Biotechnology (PBYI)
Puma Biotechnology (Nasdaq:PBYI) - Stock Price, News & Analysis - Simply Wall St
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology
Stocks to Watch: Dropbox, Nike, Tronc, Qualcomm, Puma Biotechnology, Invitation Homes, Universal Display - WSJ
Why Puma Biotechnology Is Soaring Today | The Motley Fool
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
Puma Biotechnology Inc
The Prognosis For Puma Biotechnology (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Surging
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
